| Proteasome inhibitor associated thrombotic microangiopathy JC Yui, J Van Keer, BM Weiss, AJ Waxman, MB Palmer, VD D'Agati, ... American journal of hematology 91 (9), E348-E352, 2016 | 111 | 2016 |
| Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer D Bansal, MA Reimers, EM Knoche, RK Pachynski Cancers 13 (2), 334, 2021 | 51 | 2021 |
| A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC). K Shah, A Ganapathy, A Borkowski, N Shah, D Bansal, R Beck, ... Journal of Clinical Oncology 40 (16_suppl), 5068-5068, 2022 | 11 | 2022 |
| Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report B Buzard, L Douglass, B Gustafson, J Buckley, M Roth, L Kujtan, D Bansal World Journal of Gastrointestinal Oncology 15 (10), 1829, 2023 | 2 | 2023 |
| Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow D Bansal, K Vij, GS Chang, CA Miller, JF DiPersio, R Vij, SE Heath, ... haematologica 103 (6), e270, 2018 | 2 | 2018 |
| Post-transplant outcomes in AML patients≥ 60 years of age beyond CR1 D Bansal, PK Bhamidipati, NC Edwin, M Slade, JF DiPersio, P Westervelt, ... Blood 128 (22), 4696, 2016 | 2 | 2016 |
| Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors B Ponvilawan, AW Khan, J Subramanian, D Bansal Cancers 16 (6), 1225, 2024 | 1 | 2024 |
| Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report H Mahadevia, B Ponvilawan, A Al-Obaidi, J Buckley, J Subramanian, ... Therapeutic Advances in Medical Oncology 16, 17588359241242406, 2024 | 1 | 2024 |
| Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials B Ponvilawan, P Sharma, H Mahadevia, J Subramanian, D Bansal Journal of Thoracic Oncology 18 (9), e90-e93, 2023 | 1 | 2023 |
| CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC). JM Zaretsky, D Bansal, MA Saeed, B Peng, J Luo, J Klette, MA Reimers, ... Journal of Clinical Oncology 41 (16_suppl), 5084-5084, 2023 | 1 | 2023 |
| Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers 2021, 13, 334 D Bansal, MA Reimers, EM Knoche, RK Pachynski s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| Cost of colon cancer care: Results of nationwide inpatient sample (NIS) data. P Bansal, I Rabinowitz, Y Boumber, D Bansal Journal of Clinical Oncology 35 (4_suppl), 692-692, 2017 | 1 | 2017 |
| Positive baseline thyroid autoantibodies as a predictive biomarker for thyroid immune-related adverse events: A systematic review and meta-analysis. B Ponvilawan, C Wannaphut, T Tselovalnikova, D Bansal Journal of Clinical Oncology 42 (16_suppl), e24124-e24124, 2024 | | 2024 |
| Association of chronic or acute systolic and diastolic heart failure with incidence rates of pneumonia, sepsis, and septic shock in patients with lung cancer. K Modi, H Mahadevia, S Savani, T Khumri, D Vodnala, D Bansal Journal of Clinical Oncology 42 (16_suppl), e24005-e24005, 2024 | | 2024 |
| A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review P Sharma, H Mahadevia, S Donepudi, L Kujtan, B Gustafson, ... Clinical Lung Cancer, 2024 | | 2024 |
| Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review … B Ponvilawan, H Mahadevia, H Qasim, P Sharma, D Bansal, ... Clinical Lung Cancer, 2024 | | 2024 |
| 532 A cross-cohort examination of factors impacting immunotherapy survival in non-small cell lung cancer (NSCLC) K Danilov, D Bansal, I Valiev, V Kushnarev, C Ward, A Al-Obaidi, T Pluard, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| EP11. 03-17 Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials B Ponvilawan, P Sharma, H Mahadevia, H Qasim, J Subramanian, ... Journal of Thoracic Oncology 18 (11), S627, 2023 | | 2023 |
| P1. 27-08 Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials B Ponvilawan, H Qasim, P Sharma, H Mahadevia, J Subramanian, ... Journal of Thoracic Oncology 18 (11), S286-S287, 2023 | | 2023 |
| P1. 21-16 NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy K Danilov, D Bansal, C Ward, A Al-Obaidi, T Pluard, A Tarasov, I Valiev, ... Journal of Thoracic Oncology 18 (11), S241, 2023 | | 2023 |
